Karen J Bosma, Karen E A Burns, Claudio M Martin, Yoanna Skrobik, Jordi Mancebo Cortés, Sorcha Mulligan, Myriam Lafreniere-Roula, Kevin E Thorpe, Juan Carlos Suárez Montero, Indalecio Morán Chorro, Núria Rodríguez-Farré, Ron Butler, Tracey Bentall, Gaëtan Beduneau, Pauline Enguerrand, Marlene Santos, Thomas Piraino, Savino Spadaro, Federica Montanaro, John Basmaji, Eileen Campbell, Alain Mercat, François M Beloncle, Guillaume Carteaux, Tommaso Maraffi, Emmanuel Charbonney, Marie Lecronier, Martin Dres, Yaseen M Arabi, Andre Carlos Kb Amaral, Nicole Marinoff, Neill K J Adhikari, Anna Geagea, Phil Shin, Katerina Vaporidi, Eumorfia Kondili, Jason Shahin, Josie Campisi, Pablo O Rodriguez, Mariano Setten, Ewan C Goligher, Niall D Ferguson, Vito Fanelli, Gabriela Ferreyra, Francois Lellouche, Stephanie Sibley, Laurent Brochard
{"title":"减少机械通气持续时间的比例辅助通气。","authors":"Karen J Bosma, Karen E A Burns, Claudio M Martin, Yoanna Skrobik, Jordi Mancebo Cortés, Sorcha Mulligan, Myriam Lafreniere-Roula, Kevin E Thorpe, Juan Carlos Suárez Montero, Indalecio Morán Chorro, Núria Rodríguez-Farré, Ron Butler, Tracey Bentall, Gaëtan Beduneau, Pauline Enguerrand, Marlene Santos, Thomas Piraino, Savino Spadaro, Federica Montanaro, John Basmaji, Eileen Campbell, Alain Mercat, François M Beloncle, Guillaume Carteaux, Tommaso Maraffi, Emmanuel Charbonney, Marie Lecronier, Martin Dres, Yaseen M Arabi, Andre Carlos Kb Amaral, Nicole Marinoff, Neill K J Adhikari, Anna Geagea, Phil Shin, Katerina Vaporidi, Eumorfia Kondili, Jason Shahin, Josie Campisi, Pablo O Rodriguez, Mariano Setten, Ewan C Goligher, Niall D Ferguson, Vito Fanelli, Gabriela Ferreyra, Francois Lellouche, Stephanie Sibley, Laurent Brochard","doi":"10.1056/NEJMoa2505708","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>In critically ill patients, acceleration of liberation from mechanical ventilation is important in order to reduce the risk of complications and to improve long-term outcomes. Whether the use of proportional-assist ventilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation from mechanical ventilation than pressure-support ventilation (PSV) is unclear.</p><p><strong>Methods: </strong>In this international clinical trial, we randomly assigned adult patients who had been receiving mechanical ventilation for at least 24 hours and were able to undergo partial ventilatory support with PSV but were not yet ready for liberation from ventilation to undergo PAV+ (which targeted normal work of breathing) or PSV (which targeted a normal respiratory rate and tidal volume). The primary outcome was the time from randomization to successful liberation from mechanical ventilation.</p><p><strong>Results: </strong>Across 23 centers in seven countries, 722 patients were enrolled, and 573 underwent randomization and were included in the analysis. The median time to successful liberation from mechanical ventilation was 7.3 days (95% confidence interval [CI], 6.2 to 9.7) in the PAV+ group and 6.8 days (95% CI, 5.4 to 8.8) in the PSV group (P = 0.58). The median number of ventilator-free days, the incidence of reintubation and tracheostomy, and the incidence of death by day 90 (29.6% in the PAV+ group and 26.6% in the PSV group), all of which were secondary outcomes, were similar in the two groups. With respect to sedative drugs, the mean (±SD) difference in the midazolam-equivalent dose at day 28 relative to the baseline dose was -1.51±3.28 mg per kilogram of body weight in the PAV+ group and 0.04±0.97 mg per kilogram in the PSV group. Serious adverse events occurred in 31 patients (10.8%) in the PAV+ group and in 28 patients (9.8%) in the PSV group (P = 0.79).</p><p><strong>Conclusions: </strong>The time to liberation from mechanical ventilation did not differ significantly between the group that underwent PAV+ and the group that underwent PSV. (Funded by the Canadian Institutes of Health Research and others; PROMIZING ClinicalTrials.gov number, NCT02447692.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":78.5000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.\",\"authors\":\"Karen J Bosma, Karen E A Burns, Claudio M Martin, Yoanna Skrobik, Jordi Mancebo Cortés, Sorcha Mulligan, Myriam Lafreniere-Roula, Kevin E Thorpe, Juan Carlos Suárez Montero, Indalecio Morán Chorro, Núria Rodríguez-Farré, Ron Butler, Tracey Bentall, Gaëtan Beduneau, Pauline Enguerrand, Marlene Santos, Thomas Piraino, Savino Spadaro, Federica Montanaro, John Basmaji, Eileen Campbell, Alain Mercat, François M Beloncle, Guillaume Carteaux, Tommaso Maraffi, Emmanuel Charbonney, Marie Lecronier, Martin Dres, Yaseen M Arabi, Andre Carlos Kb Amaral, Nicole Marinoff, Neill K J Adhikari, Anna Geagea, Phil Shin, Katerina Vaporidi, Eumorfia Kondili, Jason Shahin, Josie Campisi, Pablo O Rodriguez, Mariano Setten, Ewan C Goligher, Niall D Ferguson, Vito Fanelli, Gabriela Ferreyra, Francois Lellouche, Stephanie Sibley, Laurent Brochard\",\"doi\":\"10.1056/NEJMoa2505708\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>In critically ill patients, acceleration of liberation from mechanical ventilation is important in order to reduce the risk of complications and to improve long-term outcomes. Whether the use of proportional-assist ventilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation from mechanical ventilation than pressure-support ventilation (PSV) is unclear.</p><p><strong>Methods: </strong>In this international clinical trial, we randomly assigned adult patients who had been receiving mechanical ventilation for at least 24 hours and were able to undergo partial ventilatory support with PSV but were not yet ready for liberation from ventilation to undergo PAV+ (which targeted normal work of breathing) or PSV (which targeted a normal respiratory rate and tidal volume). The primary outcome was the time from randomization to successful liberation from mechanical ventilation.</p><p><strong>Results: </strong>Across 23 centers in seven countries, 722 patients were enrolled, and 573 underwent randomization and were included in the analysis. The median time to successful liberation from mechanical ventilation was 7.3 days (95% confidence interval [CI], 6.2 to 9.7) in the PAV+ group and 6.8 days (95% CI, 5.4 to 8.8) in the PSV group (P = 0.58). The median number of ventilator-free days, the incidence of reintubation and tracheostomy, and the incidence of death by day 90 (29.6% in the PAV+ group and 26.6% in the PSV group), all of which were secondary outcomes, were similar in the two groups. With respect to sedative drugs, the mean (±SD) difference in the midazolam-equivalent dose at day 28 relative to the baseline dose was -1.51±3.28 mg per kilogram of body weight in the PAV+ group and 0.04±0.97 mg per kilogram in the PSV group. Serious adverse events occurred in 31 patients (10.8%) in the PAV+ group and in 28 patients (9.8%) in the PSV group (P = 0.79).</p><p><strong>Conclusions: </strong>The time to liberation from mechanical ventilation did not differ significantly between the group that underwent PAV+ and the group that underwent PSV. (Funded by the Canadian Institutes of Health Research and others; PROMIZING ClinicalTrials.gov number, NCT02447692.).</p>\",\"PeriodicalId\":54725,\"journal\":{\"name\":\"New England Journal of Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":78.5000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New England Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1056/NEJMoa2505708\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/NEJMoa2505708","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Proportional-Assist Ventilation for Minimizing the Duration of Mechanical Ventilation.
Background: In critically ill patients, acceleration of liberation from mechanical ventilation is important in order to reduce the risk of complications and to improve long-term outcomes. Whether the use of proportional-assist ventilation with load-adjustable gain factors (PAV+) results in a shorter time to successful liberation from mechanical ventilation than pressure-support ventilation (PSV) is unclear.
Methods: In this international clinical trial, we randomly assigned adult patients who had been receiving mechanical ventilation for at least 24 hours and were able to undergo partial ventilatory support with PSV but were not yet ready for liberation from ventilation to undergo PAV+ (which targeted normal work of breathing) or PSV (which targeted a normal respiratory rate and tidal volume). The primary outcome was the time from randomization to successful liberation from mechanical ventilation.
Results: Across 23 centers in seven countries, 722 patients were enrolled, and 573 underwent randomization and were included in the analysis. The median time to successful liberation from mechanical ventilation was 7.3 days (95% confidence interval [CI], 6.2 to 9.7) in the PAV+ group and 6.8 days (95% CI, 5.4 to 8.8) in the PSV group (P = 0.58). The median number of ventilator-free days, the incidence of reintubation and tracheostomy, and the incidence of death by day 90 (29.6% in the PAV+ group and 26.6% in the PSV group), all of which were secondary outcomes, were similar in the two groups. With respect to sedative drugs, the mean (±SD) difference in the midazolam-equivalent dose at day 28 relative to the baseline dose was -1.51±3.28 mg per kilogram of body weight in the PAV+ group and 0.04±0.97 mg per kilogram in the PSV group. Serious adverse events occurred in 31 patients (10.8%) in the PAV+ group and in 28 patients (9.8%) in the PSV group (P = 0.79).
Conclusions: The time to liberation from mechanical ventilation did not differ significantly between the group that underwent PAV+ and the group that underwent PSV. (Funded by the Canadian Institutes of Health Research and others; PROMIZING ClinicalTrials.gov number, NCT02447692.).
期刊介绍：
The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
